1. 2018
  2. 2017
  3. van Vark, L. C., Lesman-Leegte, I., Baart, S. J., Postmus, D., Pinto, Y. M., de Boer, R. A., ... TRIUMPH (Translational Initiative on Unique and Novel Strategies for Management of Patients with Heart Failure) Investigators (2017). Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. Journal of the American Heart Association, 6(12). DOI: 10.1161/JAHA.116.003700
  4. Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Perrone, R. D., Koch, G., ... REPRISE Trial Investigators (2017). Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 377(20), 1930-1942. DOI: 10.1056/NEJMoa1710030
  5. Brouwer-Brolsma, E. M., Brennan, L., Drevon, C. A., van Kranen, H., Manach, C., Dragsted, L. O., ... Feskens, E. J. M. (2017). Combining traditional dietary assessment methods with novel metabolomics techniques: present efforts by the Food Biomarker Alliance. Proceedings of the nutrition society, 76(4), 619-627. DOI: 10.1017/S0029665117003949
  6. Vanholder, R., Annemans, L., Brown, E., Gansevoort, R., Gout-Zwart, J. J., Lameire, N., ... European Kidney Health Alliance (2017). Further approaches to reduce the cost of renal replacement therapy. Nature Reviews Nephrology, 13(11). DOI: 10.1038/nrneph.2017.136
  7. Mahdessian, H., Matic, L. P., Lengquist, M., Gertow, K., Sennblad, B., Baldassarre, D., ... IMPROVE Study Grp (2017). Integrative studies implicate matrix metalloproteinase-12 as a culprit gene for large-artery atherosclerotic stroke. Journal of Internal Medicine, 282(5), 429-444. DOI: 10.1111/joim.12655
  8. Pontillo, C., Zhang, Z-Y., Schanstra, J. P., Jacobs, L., Zürbig, P., Thijs, L., ... Jankowski, J. (2017). Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. Kidney International Reports, 2(6), 1066-1075. DOI: 10.1016/j.ekir.2017.06.004
  9. Cherney, D., Perkins, B. A., Lytvyn, Y., Heerspink, H., Rodriguez-Ortie, M. E., & Mischak, H. (2017). The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. Plos one, 12(10), [0186910]. DOI: 10.1371/journal.pone.0186910
  10. Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J-A., Fogo, A. B., ... ISN Global Kidney Health Summit participants (2017). Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. The Lancet, 390(10105), 1888-1917. DOI: 10.1016/S0140-6736(17)30788-2
  11. Charytan, D. M., Solomon, S. D., Ivanovich, P., Remuzzi, G., Cooper, M. E., McGill, J. B., ... Pfeffer, M. A. (2017). ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 70(4), 522-531. DOI: 10.1053/j.ajkd.2017.04.018
  12. Aghagolzadeh, P., Radpour, R., Bachtler, M., van Goor, H., Smith, E. R., Lister, A., ... Pasch, A. (2017). Hydrogen sulfide attenuates calcification of vascular smooth muscle cells via KEAP1/NRF2/NQO1 activation. ATHEROSCLEROSIS, 265, 78-86. DOI: 10.1016/j.atherosclerosis.2017.08.012
  13. Ferreira, J. P., Rossignol, P., Machu, J-L., Sharma, A., Girerd, N., Anker, S. D., ... Zannad, F. (2017). Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: Findings from BIOSTAT-CHF. European Journal of Heart Failure, 19(10), 1284-1293. DOI: 10.1002/ejhf.900
  14. Luyckx, V. A., Tuttle, K. R., Garcia-Garcia, G., Gharbi, M. B., Heerspink, H. J. L., Johnson, D. W., ... White, S. L. (2017). Reducing major risk factors for chronic kidney disease. Kidney international supplements, 7(2), 71-87. DOI: 10.1016/j.kisu.2017.07.003
Previous 1 2 3 4 5 6 7 8 ...77 Next

ID: 37499